Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of 2 repurposed drugs
(acetylsalicylic acid and ibuprofen), for use as adjunct therapy added to, and compared with,
the standard of care (SoC) WHO-recommended TB regimen in drug-sensitive (DS) and multi-drug
resistant (MDR) TB patients.
Phase:
Phase 2
Details
Lead Sponsor:
Fundació Institut Germans Trias i Pujol
Collaborators:
National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia Perinatal HIV Research Unit of the University of the Witswatersrand